Skip to content

Modality × Target Matrix — Exploration Surface

Why this page exists

Open Enzyme is a living research output of an exploration mission, not a fixed koji-platform roadmap. The wiki has historically organized around mechanism (NLRP3 chokepoints CP0-CP6) and around chassis (engineered yeast / koji), and that mostly works — but it has a blind spot: it doesn't make the orthogonal "what tools haven't we considered" search visible. When a new modality lands in the broader scientific toolset (mRNA, base editing, engineered exosomes, kidney-tropic siRNA, etc.), there's no canonical place to ask "where in the gout / NLRP3 / urate-axis map could this open a door?"

This page is that place. Rows are modalities (small molecules, peptides, engineered organisms, RNA platforms, phages, etc.). Columns are targets — anatomical/cellular sites and pathway nodes where intervention is mechanistically relevant. Each cell answers one question: what's currently in OE here, what could plausibly go here from outside, and which cells are the genuine empty-space exploration vectors.

The matrix is not an attempt to commit OE to any particular new direction. It's a navigable map of the exploration surface — kept alive so the next sweep, the next paper, the next conversation can ask "which cell does this update?" rather than "does this fit the current chassis?"

The framing question per cell, per Brian (2026-04-28): "What open questions might this modality answer at this target?" — not "is this modality useful here?" The inversion is load-bearing.

How to read this page

The matrix below uses a 5-symbol legend:

Symbol Meaning
✅ OE has live coverage at this cell — see linked wiki page
🧪 OE has an in silico-validated, wet-lab-gated engineering candidate — comp-NNN computational prior LOW or LOW-MODERATE; specific construct designed; wet-lab expression / activity confirmation pending
🔬 OE has partial / mechanism-relevant coverage; specific intervention not yet engineered
🟡 Open exploration vector — modality could plausibly answer a stuck question at this target; not currently in OE
⚪ Mechanistically possible but no realistic path / overkill / addressed by another modality
— Not applicable / mechanism doesn't intersect target

Cells marked 🟡 are where the most interesting nuggets live. Each one is a candidate "what gout-relevant problem could THIS open?" question. The "Open exploration questions" section below pulls the highest-leverage 🟡 cells into a queue.

The matrix

Targets across the top, modalities down the side. Columns grouped by anatomical site / pathway access. Click into the per-modality and per-target sections below for the full per-cell prose.

Row 1: Gut compartment targets

Modality Gut lumen (urate degradation) Gut epithelium ABCG2 (transcellular secretion) Gut macrophages (NLRP3 priming) Gut barrier (TNFα cycle / LPS leak) Gut microbiome (community shape)
Small molecules / supplements ⚪ ✅ (sulforaphane) ✅ (BHB, oridonin) ✅ (zinc-carnosine) 🔬 (berberine)
Peptides ⚪ ⚪ 🔬 (KPV) ✅ (BPC-157, KPV) —
Engineered yeast ✅ (uricase) ⚪ 🟡 (yeast-cell-wall β-glucan local NLRP3?) 🔬 (transit organism) 🟡
Engineered koji ✅ (uricase, carnosine, lactoferrin) 🟡 (glucoraphanin co-production — see open-questions) 🔬 (kojic acid, ergothioneine local) ✅ (lactoferrin TNFα suppression) 🔬
Native-compound medicinal mushroom complement 🔬 (whole Cordyceps fermentate delivers cordycepin + native pentostatin ADA-inhibitor pairing; mushroom polysaccharides shape gut microbiome → indirect luminal urate effects via Bacteroides purine fermentation) 🔬 (GLPP modulates ABCG2/GLUT9/OAT1 expression in HUA mice PMID 36385640; FZ-Poria multi-herb formula PMID 37788785) 🔬 (β-glucan structure-dependent NLRP3 — G. lucidum EPS activate, spore-powder/GLP inhibit per comp-014 Phase 5; ergothioneine via Keap1/Nrf2 anti-priming) ✅ (ergothioneine via OCTN1, P. citrinopileatus 50-100g/day delivers therapeutic dose; β-glucans general gut-barrier effect) ✅ (mushroom polysaccharides extensively shape microbiome — established literature; central to whole-fermentate-mushroom mechanism)
Engineered LBPs (obligate anaerobes — Bacteroides / Faecalibacterium / Akkermansia) 🟡 (genuine colonization vs. yeast/koji transit) 🟡 (engineered Faecalibacterium for local butyrate at crypt) 🟡 🟡 (engineered Akkermansia for mucus-layer repair) 🟡 (community-level by design)
Engineered E. coli Nissle ✅ (PULSE) ⚪ 🟡 🟡 (engineered IL-22 secretion) 🟡
Bacteriophages — ⚪ ⚪ 🟡 (selective suppression of LPS-producing gram-negatives) 🟡 (selective rather than additive)
Microbiome consortia / FMT — ⚪ ⚪ 🔬 🟡 (community-level)
Engineered exosomes ⚪ 🟡 (oral-route exosomes carrying ABCG2-inducer) 🟡 (macrophage-tropic NLRP3 silencer) 🟡 (claudin / ZO-1 modulator delivery) —
mRNA / saRNA / circRNA + LNP ⚪ ⚪ (oral mRNA still research-stage) 🟡 (myeloid-tropic LNP NLRP3 silencer) ⚪ —
siRNA / ASOs ⚪ ⚪ 🟡 (myeloid-tropic NLRP3 / NF-κB silencer) 🟡 (TNFα siRNA local) —
CRISPR / base editing in patient — 🟡 (Q141K → Q141 base edit in crypt stem cells; delivery unsolved) ⚪ ⚪ —
Antibodies / biologics — ⚪ ⚪ ⚪ (anti-TNFα systemic; overkill) —
Engineered soluble complement regulators (sCR1, Factor H, DAF/CD55) — — 🧪 (DAF/CD55 SCR1-4 truncated in silico-validated 2026-05-05 — LOW protease risk in shio-koji per comp-012, identical to uricase. CP0 status moved from "honest platform gap" to "active engineering candidate, three wet-lab unknowns documented in hypotheses/H05". Wet-lab gate formalized 2026-05-06 as validation-experiments.md §1.25 — single-cassette routing per chaperone framework triple-cassette prediction below 0.6 decision gate. Two-chassis CP0 architecture substantiated 2026-05-17: comp-037 returned MODERATE for C1-INH (SERPING1) on EcN-LBP — serpin-core construct aa 123–500, LOW strictly-degradative risk, GREEN glycosylation feasibility, kinetic-competition gated at the RCL. C1-INH at classical/lectin entry + DAF SCR1-4 at surface convertase decay = two independent mechanisms at two cascade points via two independent chassis.) ⚪ —
Pharmacological chaperones — 🟡 (Q141K folding rescue à la CFTR-corrector class) ⚪ ⚪ —
SPM precursors (DHA → RvD1/MaR1) — 🔬 ✅ (SPM) 🔬 —
Fermentable fiber / prebiotics — ✅ (butyrate → PPARγ → ABCG2) 🔬 🔬 (mucus-layer support) ✅
Native-compound medicinal mushroom complement 🔬 (GLPP from G. lucidum — 40.6% UA reduction in HUA mice via ADA inhibition + GLUT9/OAT1, PMID 36385640; cordycepin from C. militaris — URAT1 modulation 337→203 µmol/L, PMID 29422889; whole C. militaris water extract — HUA rat serum UA 281.62→93.27 µmol/L at 0.5 g/(kgd), Xiong 2024 Biotechnology Bulletin, DOI 10.13560/j.cnki.biotech.bull.1985.2024-0379; S. vaninii* ethanol/whole extract — Animal Model HUA signals via XOD + urate-transporter expression, DOI 10.1016/j.biopha.2023.114970 / 10.3390/nu14204421; whole-fermentate Cordyceps includes natural pentostatin ADA-inhibitor pairing per Phase 7-1b) 🔬 (FZ-formula Poria cocos multi-herb modulates ABCG2/GLUT9/OAT1 + NLRP3, PMID 37788785 — multi-herb attribution issue per comp-014 Phase 6; GLPP modulates GLUT9/OAT1 directly; C. militaris water extract modulates URAT1/GLUT9/OAT1/ABCG2 in HUA rats; S. vaninii SHEE promotes OAT1/OAT3/ABCG2 and inhibits URAT1/GLUT9 in HUA renal-injury mice) 🔬 (C. militaris water extract reduces renal NLRP3 / IL-1β inflammatory markers in HUA rats, but not an MSU-flare model; S. vaninii / I. hispidus reduce ankle swelling and inflammatory markers in MSU-induced acute gouty arthritis rats; β-glucans + ergothioneine modulate NLRP3 — directionality structure-dependent per Phase 5: G. lucidum exopolysaccharides ACTIVATE; spore powder + GLP β-glucan INHIBIT; phase-6 methodology constraint) ✅ (ergothioneine via OCTN1/SLC22A4 absorption — dietary 50-100 g fresh oyster delivers 12-24 mg, within RCT-investigational range per Phase 7-1c; P. citrinopileatus is highest fungal producer 7.0 mg/g DW; β-glucans general gut-barrier support) ✅ (mushroom polysaccharides extensively shape gut microbiome — well-established literature; lentinan, GLPP, pleuran, PSK all documented; C. militaris water extract improved microbiome diversity in HUA rats)
Compounding pharmacy (503A/503B) ⚪ (proteins/enzymes not compoundable — stay on fermentation chassis) ⚪ ⚪ ⚪ ⚪

Row 2: Renal compartment targets

Modality Kidney URAT1 / GLUT9 (renal reabsorption) Kidney ABCG2 (renal secretion) Kidney macrophages (urate nephropathy)
Small molecules / supplements 🔬 (carnosine — animal model only) 🔬 (fenofibrate adjacent) 🔬
Peptides ⚪ ⚪ ⚪
Engineered yeast — — —
Engineered koji — — —
Engineered LBPs — 🟡 (systemic SCFA from gut → renal PPARγ?) —
Native-compound medicinal mushroom complement 🔬 (GLPP animal URAT1/GLUT9 expression-level modulation PMID 36385640; cordycepin mouse SUA 337→203 µmol/L PMID 29422889; whole C. militaris water extract HUA rat serum UA 281.62→93.27 µmol/L with URAT1/GLUT9 down, Xiong 2024 Biotechnology Bulletin DOI 10.13560/j.cnki.biotech.bull.1985.2024-0379; S. vaninii SHEE lowers UA/Cr/BUN/XOD and suppresses URAT1/GLUT9 in HUA renal-injury mice, DOI 10.1016/j.biopha.2023.114970; P. igniarius TFPI lowers UA 105.0→82.3 micromol/L and liver XOD 48.91→44.09 U/g prot at 450 mg/kg in HUA/UN mice, DOI 10.1016/j.heliyon.2023.e12979; DAE dual XO+URAT1 effect PMID 35750011) 🔬 (GLPP increases OAT1 in mice; C. militaris water extract upregulates OAT1/ABCG2 in HUA rats; S. vaninii SHEE promotes OAT1/OAT3/ABCG2 in HUA renal-injury mice; P. igniarius TFPI increases ABCG2 protein in MSU-treated HK-2 renal cells; FZ-Poria multi-herb confounded for ABCG2) 🔬 (C. militaris water extract reduced renal oxidative-stress / inflammatory markers including NLRP3 and IL-1β in HUA rats; S. vaninii SHEE reduced HUA renal-injury/apoptosis markers; P. igniarius TFPI reduced TLR4/NF-kB/TXNIP/NLRP3 and IL-1β/TNF-α in MSU-treated HK-2 renal cells; ergothioneine OCTN1-mediated tissue distribution may reach kidney macrophages but remains indirect)
Engineered E. coli Nissle — — —
Bacteriophages — — —
Microbiome consortia / FMT ⚪ ⚪ ⚪
Engineered exosomes 🟡 (kidney-tropic exosomes carrying URAT1 inhibitor) 🟡 🟡
mRNA / saRNA / circRNA + LNP 🟡 (kidney-tropic LNPs are research-active; mRNA encoding URAT1-blocker?) 🟡 (mRNA encoding wild-type ABCG2 to renal tubule) 🟡 (NLRP3-silencer mRNA)
siRNA / ASOs 🟡 (kidney-tropic siRNA against URAT1 mRNA — the cleanest "elegant solution"; megalin-binding conjugates are an active class) 🟡 🟡
CRISPR / base editing in patient 🟡 (renal tubule editing — delivery hard) 🟡 (Q141K rescue at renal expression — same problem) ⚪
Antibodies / biologics ⚪ ⚪ ⚪
Pharmacological chaperones 🟡 (URAT1 destabilizer / GLUT9 destabilizer — research-class for renal transporters) 🟡 (Q141K folding rescue at renal site) —
SPM precursors — — 🔬
Fermentable fiber / prebiotics — 🔬 (systemic SCFA → modest renal effect) —
Native-compound medicinal mushroom complement 🔬 (cordycepin URAT1 modulation animal evidence PMID 29422889; GLPP GLUT9 down + OAT1 up PMID 36385640; P. igniarius TFPI lowers serum UA and liver XOD in HUA/UN mice but does not establish direct URAT1 binding; these are expression / pathway-level signals — comp-014 Phase 5 plus P0-1 source-read finding) 🔬 (GLPP modulates renal OAT1 expression; P. igniarius TFPI increases ABCG2 protein in MSU-treated HK-2 renal cells; FZ-formula Poria increases ABCG2 expression — multi-herb confounded) 🟡 (ergothioneine OCTN1-mediated tissue distribution may reach kidney macrophages but no direct evidence in comp-014 scan; open exploration vector)
Compounding pharmacy (503A/503B) ✅ (allopurinol custom doses + probenecid combos — see compounding-pharmacy-track.md) ⚪ ⚪

Row 3: Tissue-resident NLRP3 sites + acute flare

Modality Synovial macrophages (joint flare site) Vessel-wall macrophages (Lp-PLA2 / chronic vascular inflammation) Acute flare termination (IL-1β block)
Small molecules / supplements ✅ (systemic BHB, oridonin, EGCG) 🔬 (same systemic compounds, low local concentration) 🔬 (colchicine, prednisone)
Peptides ⚪ (systemic peptides poorly absorbed) ⚪ ⚪
Engineered yeast / koji — — ⚪ (chronic only — no fast onset)
Native-compound medicinal mushroom complement 🔬 (S. vaninii / I. hispidus extracts reduced ankle swelling and inflammatory markers in MSU-induced acute gouty arthritis rats; β-glucan + hispolon Phellinus + ergothioneine remain systemic anti-inflammatory layers, not proven synovium-targeted delivery) 🔬 (ergothioneine OCTN1 distribution to vessel-wall macrophages; weak/indirect Lp-PLA2 evidence) ⚪ (chronic supplement context, slow onset; not flare-termination tool)
Engineered LBPs — 🟡 (systemic SCFA → vessel-wall PPARγ?) —
Bacteriophages — — —
Engineered exosomes 🟡 (intra-articular exosome carrying NLRP3 inhibitor) 🟡 (CD163 / mannose-receptor-tropic exosomes for Lp-PLA2 source macrophages) 🟡 (rapid IL-1RA delivery)
mRNA / saRNA / circRNA + LNP 🟡 (intra-articular mRNA-IL-1RA at flare onset) 🟡 (myeloid-tropic LNP delivering NLRP3-silencer mRNA — the genuinely novel angle for Lp-PLA2) 🟡 (mRNA-IL-1RA pulse therapy IV — fits because flare is short-window; transient expression IS the right shape)
siRNA / ASOs 🟡 (NLRP3 silencer in joint tissue) 🟡 (NLRP3 / NF-κB silencer in vessel-wall macrophages) ⚪ (too slow for acute)
CRISPR / base editing in patient ⚪ ⚪ ⚪
Antibodies / biologics ✅ (canakinumab, anakinra — exist, expensive) 🔬 (no current biologic for vessel-wall NLRP3 specifically) ✅ ($300K/yr canakinumab — the existing high-cost option)
Pharmacological chaperones ⚪ ⚪ ⚪
SPM precursors ✅ (SPM — RvD1/MaR1 in animal MSU model) 🔬 (DHA-emphasis rationale per tnfsf14) 🔬
Fermentable fiber — 🔬 (systemic anti-inflammatory) ⚪
Native-compound medicinal mushroom complement 🔬 (S. vaninii / I. hispidus extracts reduced ankle swelling and inflammatory markers in MSU-induced acute gouty arthritis rats; β-glucans + hispolon from Phellinus + ergothioneine remain broader systemic anti-inflammatory effects) 🔬 (ergothioneine OCTN1-mediated tissue distribution; eritadenine cardiovascular activity from shiitake; weak direct Lp-PLA2 evidence — Phase 5 found this gap) ⚪ (slow-onset chronic supplement context, not flare-termination tool — same limitation as engineered yeast/koji row)
Compounding pharmacy (503A/503B) 🔬 (colchicine custom doses for acute flare — see compounding-pharmacy-track.md) ⚪ 🔬 (colchicine and prednisone already standard; compounding adds custom-dose flexibility)

Row 4: Monitoring / detection

Modality Real-time UA monitoring Chokepoint biomarker readout Microbiome state monitoring
Lab panel (Quest / clinical) ✅ (intermittent) 🔬 (self-experiment-protocol — pending CP-biomarker map per synthesis archive #4) ⚪
Wearable sensors 🟡 (sweat UA — UCSD / Stanford research; ~5 yr from clinical) ⚪ ⚪
Microneedle patches 🟡 (continuous interstitial UA — research-stage CGM-equivalent) ⚪ ⚪
Implantable monitors 🟡 (overkill for gout-only; unit economics flip if multi-marker) 🟡 (multi-analyte) ⚪
Stool 16S / shotgun sequencing ⚪ ⚪ 🔬 (Onegevity, Viome — getting cheaper)
At-home immune-cell profiling ⚪ 🟡 (citH3 / cfDNA / aggNET ratio per synthesis archive #7) ⚪
Native-compound medicinal mushroom complement ⚪ ⚪ ⚪

Per-modality details (rows)

Engineered yeast / koji

Compounding pharmacy (503A/503B) — delivery route, not chassis

  • Strengths: lowest engineering effort of any peer track — formulation engineering only (release matrix, dose, dissolution profile), no genetic engineering, no drug discovery. MINX-style pattern: AI-aided formulation review + lipid-matrix release-control design + 503A compounding pharmacy + dissolution testing → days, not years. The active ingredient is already FDA-approved; the work is formulation engineering.
  • Cleavage rule: small-molecule + FDA-approved API + off-patent / off-label → compoundable. Proteins / enzymes / biologics stay on fermentation chassis.
  • Coverage gaps relative to current OE: the wiki had no delivery-route page for the repurposing surface until the compounding-pharmacy-track.md scope page (committed 2026-05-11). The discovery engine surfaces FDA-approved drugs hitting gout chokepoints; compounding is the output side that turns identification into access.
  • Highest-priority candidate: disulfiram (CP6b GSDMD inhibitor, FDA-approved for AUD, off-patent, bulk API available). Secondary candidates: colchicine custom doses, allopurinol custom doses, probenecid combos, zileuton (bulk API uncertain), pentostatin/cordycepin pairing.
  • Regulatory class: 503A (patient-specific Rx) or 503B (registered outsourcing facility). Off-label prescribing is physician's discretion.
  • Critical limitation: does NOT replace clinical trials. Compounding is an access path, not an evidence path. The discovery engine still has to do the science.
  • Dedicated scope page (committed 2026-05-11): compounding-pharmacy-track.md. 7 Phase 2 follow-ups queued (bulk API audit, pharmacy partner ID, physician partner pathway, USP characterization library, insurance reality, disulfiram dose modeling comp-NNN, sweep-daemon discovery-engine hook). (source: compounding-pharmacy-track.md)

Native-compound medicinal mushroom complement (Phase 7 peer track)

  • Strengths: lightest engineering effort of any peer track — strain selection + cultivation optimization + extract characterization, NO genetic engineering. Multiple species are already GRAS food (Pleurotus, Lentinula, Hericium); others are established supplement-grade (Ganoderma, Cordyceps, Trametes, Inonotus). Decades-to-centuries traditional-use precedent. Easiest home-cultivation UX of the platform — consumer mushroom grow kits cover most candidate species; 4-6 weeks oyster, 6-12 weeks reishi/cordyceps. Zero GMO regulatory burden.
  • Coverage gaps relative to current OE: the existing wiki had no row for native-compound producers as a modality class — until comp-014 Phase 7 (committed 2026-05-06). Open exploration questions are now consolidated in the medicinal-mushroom-complement-track.md scope page.
  • Top compounds (per comp-014 Phase 6 triage and Phase 7-1 strain scans):
  • GLPP polysaccharide-peptide (Ganoderma lucidum / lingzhi) — ADA + GLUT9 + OAT1; 40.6% UA reduction HUA mice (PMID 36385640). MW figure (520 kDa) needs Phase 5b verification — Lin lab's GL-PP is 37 kDa, GL-PP2 is 31 kDa.
  • Cordycepin / whole C. militaris water extract — purified cordycepin has URAT1-modulation animal evidence; Xiong 2024 Biotechnology Bulletin adds whole-water-extract Animal Model evidence in HUA rats (serum UA 281.62→93.27 µmol/L at 0.5 g/(kgd), URAT1/GLUT9 down, OAT1/ABCG2 up, hepatic XOD down). Whole-fermentate includes natural pentostatin ADA-inhibitor co-product. Also producible in food-grade A. oryzae via cns1+cns2 koji-engineering route* (Jeennor 2023, PMID 38071331) — cordycepin spans both peer tracks, though OE currently prefers cultivation/extract over koji engineering.
  • Sanghuangporus vaninii ethanol/whole extract — HUA renal-injury mouse evidence via XOD plus renal urate-transporter expression (URAT1/GLUT9 down; OAT1/OAT3/ABCG2 up; DOI 10.1016/j.biopha.2023.114970); separate rodent paper includes both YEP/OXO HUA mice and MSU-induced acute gouty arthritis rats (DOI 10.3390/nu14204421). Still Animal Model only; batch identity / extract standardization are SOP-gated.
  • Phellinus igniarius TFPI — HUA / uric-acid-nephropathy mouse evidence via serum UA, creatinine, and liver XOD reduction, plus MSU-treated HK-2 renal-cell TLR4/NLRP3 suppression and ABCG2 protein upregulation (DOI 10.1016/j.heliyon.2023.e12979). Still Animal Model + renal-cell evidence only; the 2025 CNKI TFPI transporter mRNA/protein nuance remains full-text-needed.
  • Ergothioneine (P. citrinopileatus — golden oyster — highest fungal producer 7.0 mg/g DW; P. ostreatus easiest cultivation 2.4 mg/g DW) — Keap1/Nrf2/HO-1 redox modulator; folds into NLRP3 axis as priming-layer inhibitor (Phase 5 verdict, redox standalone REJECT, fold into NLRP3).
  • Eritadenine (Lentinula edodes / shiitake) — cardiovascular cholesterol-lowering; vessel-wall NLRP3-adjacent.
  • Erinacines / hericenones (Hericium erinaceus / lion's mane) — NGF-inducing CNS-relevant.
  • PSK / PSP (Trametes versicolor / turkey tail) — β-glucan immunomodulator; FDA-approved adjuvant in Japan.
  • Inotodiol / betulinic acid derivatives (Inonotus obliquus / chaga) — triterpenoid chemistry.
  • Critical product-thesis advantage: regulatory simplicity. All candidate species are GRAS food or established supplement-grade — no GRAS-pathway-certification required (unlike koji-engineering tracks). Existing supplement industry framework (DSHEA US / equivalent elsewhere). Open Enzyme's value-add is reproducibility + characterization layer on top of an industry with documented quality issues (93-100% of US "G. lucidum" supplements are species-mis-IDed per Loyd 2018, Gunnels 2020).
  • Critical limitation flagged: does not displace the koji-engineering track. Koji handles secreted recombinant enzymes (uricase, lactoferrin, DAF SCR1-4); medicinal mushrooms cover compounds koji cannot reach (polysaccharide-peptides, nucleoside analogs, terpenoids). The two tracks are complementary, not substitutional. Combined consumption: daily shio-koji condiment (uricase) + weekly reishi tea (GLPP) + dinner oyster mushroom (ergothioneine).
  • Dedicated scope page (committed 2026-05-06): medicinal-mushroom-complement-track.md formalizes the parallel track sibling to engineered koji / engineered LBPs / siRNA discovery. Six Phase 7 follow-ups queued:
  • Strain selection lit scan ✅ (Phase 7-1, multilingual, 2026-05-06)
  • Cultivation method × yield meta-analysis ✅ (Phase 7-2, 2026-05-06)
  • Extract characterization protocol SOPs (Phase 7-3, queued)
  • GLPP+cordycepin synergy wet-lab gate — now 4-arm with the natural Cordyceps pentostatin pairing reframing (Phase 7-4, queued)
  • H06 hypothesis card — falsification dimensions for track viability ✅ (stub committed 2026-05-06)
  • Modality-chokepoint-matrix native-compound row — this entry ✅ (Phase 7-6, 2026-05-06)

Engineered LBPs (obligate anaerobes — Bacteroides / Faecalibacterium / Akkermansia)

  • Strengths: genuine colonization vs. transit. Faecalibacterium prausnitzii engineering is the obvious play for sustained colonic butyrate (relevant to abcg2-modulators.md ABCG2 induction + Q141K rescue). Akkermansia muciniphila is mucus-layer-resident — the natural barrier-repair chassis. Bacteroides offers the broadest metabolic engineering toolkit (Sonnenburg lab, others).
  • Coverage gaps relative to current OE: the wiki has no dedicated page on this chassis class. Brian-side Pendulum probiotic uses Akkermansia + butyrate-producers commercially; the engineering thesis for OE hasn't been developed.
  • Open exploration questions: see open-questions.md §"Co-engineered substrate-supply mechanisms". Engineered Faecalibacterium for local butyrate is the highest-leverage candidate.
  • Regulatory class: LBP framework (FDA 2018 guidance); same general lane as PULSE-style engineered E. coli Nissle, distinct from yeast/koji food path. Worth a dedicated wiki page.
  • Critical product-thesis limitation: obligate anaerobes cannot be home-fermented. The Open Enzyme home-fermentation thesis (grow koji at home, make shio-koji or amazake condiment) does not transfer to F. prausnitzii or Akkermansia — these are strict anaerobes requiring anaerobic bioreactor culture, cold-chain stabilization, and regulatory handling as Live Biotherapeutic Products (LBPs). An engineered F. prausnitzii is a commercial pharmaceutical product, not a home recipe. This is a fundamental platform-type distinction: LBP vector = commercial manufacturing + distribution track, not the "democratized home access" track the koji chassis enables.
  • Dedicated scope page (committed 2026-05-05): engineered-lbp-chassis.md formalizes this row as a peer track to the koji chassis under the broader Open Enzyme mission. Six in silico Phase 2 follow-ups are queued (engineering toolkit lit scan, commercial/clinical landscape lit scan, FDA LBP regulatory path lit scan, comp-008 F. prausnitzii expression feasibility, falsification card H02, comparative chassis matrix for gout). Phase 3 (content-triggered): platform-framing reflection on whether the LBP track justifies expanding Open Enzyme's framing from "engineered enzymes in koji" to "solve gout, every avenue, fully open."

Bacteriophages

  • Strengths: selective suppression rather than additive probiotic. Could selectively reduce LPS-producing gram-negatives (gut barrier / TNFα cycle relief), purine-fermenting Bacteroides species (luminal urate substrate reduction), or specific dysbiosis patterns identified by sequencing.
  • Current OE coverage: zero. No wiki page.
  • Clinical context: approved in several Eastern European jurisdictions; compassionate-use US; clinical programs at Adamas, Locus, Phaxiam, BiomX. AMR-associated infection is the lead indication; microbiome-modulation indications are next wave.
  • Open exploration questions: does selective phage-mediated gut microbiome reshaping shift serum UA in hyperuricemia models? Does it reduce hs-CRP / Lp-PLA2 in chronic-inflammation gout patients? No clinical data, but mechanistically defensible — the Open Enzyme thesis would benefit from explicitly evaluating phages as a complementary modality to engineered organisms.

mRNA / saRNA / circRNA platforms

  • Strengths: transient expression (good for pulse therapy), sequence-specific (any encodable protein), lipid nanoparticle delivery (LNP) is a maturing platform.
  • Best-fit cells in the matrix:
  • Acute flare termination via IV mRNA-IL-1RA pulse. Transient expression IS the right shape — flare is short-window. mRNA-IL-1RA is a hypothetical canakinumab-equivalent at variable cost. Currently zero programs.
  • Myeloid-tropic LNP delivering NLRP3-silencing mRNA / siRNA to vessel-wall macrophages. Brian's persistent Lp-PLA2 across panels is exactly the source — chronically activated vessel-wall macrophages. Acuitas, Moderna, others have myeloid-tropic LNP programs (mostly oncology-directed). For gout: nobody.
  • Worst-fit cells: anything renal (kidney-tropic LNPs immature), anything in the gut (oral mRNA still research-stage), anything requiring durability (mRNA half-life is days at best).
  • Adjacent platforms worth tracking: self-amplifying mRNA (saRNA) for lower dose / longer expression; circular RNA (circRNA) for resistance to exonucleases (Orna Therapeutics); these change the durability calculus.

siRNA / ASOs

  • Dedicated scope page (committed 2026-05-05): sirna-urat1-modality.md formalizes the kidney-tropic siRNA / URAT1 vector (the matrix's #1 open exploration question) as a discovery-engine output — non-fermentable, positioned for partner / spinout development. Sister page to engineered-lbp-chassis.md under the chase-every-avenue framing. Six in silico Phase 2 follow-ups queued (kidney-tropic conjugate chemistry lit scan, comp-009 URAT1 mRNA target site analysis, commercial landscape lit scan, comparative analysis vs. pozdeutinurad-class small-molecule URAT1 inhibitors, falsification card H03, FDA siRNA regulatory path lit scan).
  • Strengths: sequence-specific knockdown of any expressed gene; GalNAc conjugates already approved (inclisiran, patisiran) for liver targets; kidney-tropic conjugate chemistry is an active research class (megalin binding, kidney-cortex selectivity).
  • Best-fit cells in the matrix:
  • Kidney URAT1 silencing. This is the cleanest "elegant solution" in the entire matrix: sequence-specific knockdown of the renal-reabsorption transporter that drives Brian's hyperuricemia phenotype. Eliminates the dose-dependent off-target profile of small-molecule URAT1 inhibitors (benzbromarone hepatotoxicity). No clinical program for gout that I know of.
  • Macrophage NLRP3 silencing — slower than mRNA-IL-1RA pulse but more durable.
  • Local TNFα siRNA in gut macrophages — finer than systemic anti-TNFα biologic.
  • Worst-fit cells: acute flare (too slow), anything that requires de novo protein expression rather than knockdown.

CRISPR / base editing / prime editing in patient

  • Strengths: durable correction, single-edit mechanism for Q141K-style point variants.
  • Best-fit cells: Q141K → Q141 base edit in gut crypt stem cells. Mechanistically perfect; delivery unsolved.
  • Worst-fit cells: everything else. Differentiated tissue editing wastes the durability advantage; nothing approved for non-hematopoietic somatic editing yet.
  • Status: wait-and-see. Five-to-ten-year horizon for the delivery side. The OE thesis competes by sidestepping the editing problem entirely (gut-lumen sink + ABCG2 induction).

Pharmacological chaperones

  • Strengths: small molecules that bind misfolded protein variants (e.g., Q141K) and rescue trafficking. CFTR-corrector class (ivacaftor, tezacaftor, elexacaftor) is the precedent — multibillion-dollar therapeutic class for ΔF508 in CF.
  • Best-fit cells: Q141K folding rescue at the gut and renal sites simultaneously, oral systemic delivery. Pharmacologically similar to the CFTR play.
  • Current research activity for ABCG2 Q141K specifically: academic literature exists (Basseville 2012, others); no clinical programs. The market is small (gout has cheap alternatives), but mechanistically this is the cleanest non-genetic Q141K solution.
  • Open exploration question: is the CFTR-corrector class chemistry transferable to ABCG2? Same ATP-binding cassette superfamily; the design problem is similar.

Engineered exosomes

  • Strengths: native cell-derived nanocarriers; bilayer + surface-marker engineering; can carry small molecules, peptides, RNA, or proteins; cell-tropic via surface marker selection.
  • Best-fit cells:
  • Macrophage-tropic exosomes carrying NLRP3 inhibitors (Lp-PLA2 source). CD163 or mannose-receptor display.
  • Kidney-tropic exosomes carrying URAT1 inhibitors or chaperones.
  • Intra-articular exosomes for acute flare carrying IL-1RA or NLRP3 silencer.
  • Status: research-stage clinically; Codiak/Lonza alumni and several startups (Vesigen, Aegle, Ilias). For OE: a future complementary modality, not a near-term build.

Engineered soluble complement regulators (sCR1, Factor H, DAF/CD55)

  • Strengths: closes the only "honest platform gap" in the OE corpus. complement-c5a-gout.md identifies CP0 (complement priming via C5a) as a dominant upstream chokepoint with no fermentable coverage — and validation-experiments.md §1.21 (executed 2026-04-27) confirmed via computational scan of ChEMBL / NPASS / LOTUS / Open Targets that no validated natural-product C5aR1 antagonists exist. This forced the platform to formally accept avacopan (a prescription pharma drug) as a permanent adjunct — awkward against the "your microbe makes the medicine" thesis. The unexplored alternative is to express endogenous human soluble complement regulators heterologously in the gut: sCR1 (soluble complement receptor 1), Factor H fragments, or DAF/CD55 ectodomain — proteins that already exist clinically as systemic IV biologics for autoimmune disease but have never been engineered for gut-luminal mucosal-complement coverage.
  • Best-fit cells in the matrix: gut macrophages NLRP3 priming (the CP0 step); plausibly gut barrier (complement deposition contributes to barrier dysfunction).
  • Coverage gap relative to current OE: the wiki has no page on this. All four candidate proteins (sCR1, Factor H, DAF/CD55, CD46) are in the human proteome — UniProt-fetchable, AlphaFold-modelled, MEROPS-screenable for shio-koji compatibility (the same comp-NNN protease-stability framework used for uricase and lactoferrin would apply directly).
  • Open exploration questions:
  • Can a soluble complement regulator be expressed in A. oryzae or S. cerevisiae at gut-luminal concentrations meaningful for mucosal C5a neutralization? sCR1 is ~190 kDa with 30 SCR domains — possibly too large for koji secretion. Factor H is ~150 kDa with 20 SCR domains. DAF (CD55) ectodomain is ~70 kDa with 4 SCR domains — likely the most tractable engineering target.
  • Does mucosal C5a inhibition (luminal-side) meaningfully blunt CP0 priming? The macrophages doing the priming are submucosal — does luminal sCR1 / Factor H reach them, or does it require basolateral access?
  • Same protease-stability question as uricase / lactoferrin: do the SCR (short consensus repeat) domains survive the koji fermentation environment? Run a comp-NNN analysis (e.g., comp-006) on the AlphaFold model of CD55 before any wet-lab engineering.
  • Status: zero programs. All systemic complement-regulator biologics (TP10/sCR1 by Avant, mirococept by Univ. Oxford, ARC1905 anti-C5 aptamer) target IV / intravitreal delivery for autoimmune indications. A gut-luminal mucosal-complement strategy is genuinely unexplored and well-aligned with the OE chassis.
  • comp-006 protease-stability result (2026-05-05, Mechanistic Extrapolation): AlphaFold pLDDT analysis of DAF/CD55 (P08174) under shio-koji conditions (17.5% NaCl, pH 4.5–5.0) returned HIGH for the soluble ectodomain (aa 35–353, max risk score 0.388, worst protease NPr). The verdict is stalk-contingent: the Ser/Thr-rich stalk (aa 286–353, pLDDT 30–52) is fully disordered and drives all 9 NPr-exposed and 48 ALP-exposed ectodomain sites. The SCR1–4 domains (aa 35–285, pLDDT 85–98) contribute zero exposed sites. A stalk-truncated construct (aa 35–285, SCR1–4 only) would likely return a LOW verdict — comp-007 is the logical follow-up. See wiki/daf-cd55-protease-stability-computational.md.
  • Regulatory class: if expressed in food-grade GRAS organism (koji, S. boulardii), this stays in the OE chassis lane — distinct from the systemic sCR1 biologic regulatory path. Same lane as engineered uricase / lactoferrin.

Microbiome consortia / FMT

  • Strengths: community-level intervention rather than single-strain. Vowst (Seres) FDA-approved 2023 for C. diff is the precedent.
  • Best-fit cells: gut microbiome reshaping at community level; gut barrier; potentially distal effects via systemic SCFA.
  • Status: zero programs for gout. Mechanistically defensible — adjacent indications (IBD, C. diff, metabolic syndrome) have positive signals.

Antibodies / biologics

  • Existing in gout: rasburicase, pegloticase (uricase variants — IV protein replacement, refractory gout). Canakinumab (IL-1β biologic, FDA-approved for gout 2023, very expensive). Anakinra (IL-1RA, off-label). All addressed in gout-clinical-pipeline.md.
  • Coverage gap: the wiki tracks the existing biologics but doesn't catalog them as a modality class with their own row of cells where novel engineering could land (e.g., bispecifics, Fc-fusion uricases, CD163-targeted ADCs delivering NLRP3 inhibitors to Lp-PLA2-source macrophages).

Wearable / implantable monitoring

  • Best-fit cells: real-time UA monitoring; multi-analyte chokepoint biomarker readout.
  • Status: sweat-based UA sensors are research-active (UCSD, Stanford); microneedle continuous monitoring is research-stage. Implantable multi-analyte is overkill for gout-only but flips when bundled with cardiometabolic indications.
  • Why this matters for OE: any therapeutic intervention that's titrated against UA (carnosine dose, fiber load, clomid titration for the androgen-driven case) benefits from continuous data over discrete quarterly panels. The synthesis-queue chokepoint-biomarker map (synthesis/ #4) is partly bottlenecked by infrequent sampling.

Per-target details (columns)

Gut lumen

The most-developed target in the OE wiki — the gut-lumen sink is the platform's thesis. Multi-modal coverage is solid (yeast, koji, E. coli Nissle precedent). Gap: phages and microbiome-consortia don't appear; both are mechanistically relevant for shaping the microbial community whose metabolism produces the urate substrate.

Gut epithelium ABCG2

Fairly well-covered via fiber → butyrate → PPARγ. Sulforaphane (Nrf2) supplements; glucoraphanin co-production in koji is open (per abcg2-modulators.md Engineering Implications #1). The Q141K rescue mechanism sits adjacent.

Gut macrophages

Small molecules systemic absorption is the current lever. Local action via engineered organisms (β-glucan from yeast cell wall, kojic acid from koji metabolites, KPV via PepT1 absorption) is partial. RNA-platform delivery (LNP-targeted to gut myeloid cells) is open and unexplored.

Gut barrier

Peptide layer (BPC-157, KPV, zinc-carnosine) + lactoferrin co-expression in koji + fermentable fiber. Engineered Akkermansia and engineered IL-22-secreting probiotics are the obvious novel additions.

Gut microbiome (community shape)

Berberine (small molecule) + fermentable fiber. Phages and microbiome consortia are the modalities specifically built for community-level intervention; both absent from the wiki.

Kidney URAT1 / GLUT9

The biggest coverage gap in the matrix. Carnosine is the only OE-relevant modality, and it's animal-model evidence only. siRNA against URAT1 mRNA via kidney-tropic conjugates is the cleanest novel angle in the entire matrix — sequence-specific, no off-target small-molecule profile, eliminates the historical benzbromarone hepatotoxicity concern.

Kidney ABCG2

Indirect coverage via systemic SCFA from gut fiber. Direct kidney-targeted ABCG2 induction is open; pharmacological chaperones for Q141K at the renal site are open.

Kidney macrophages (urate nephropathy)

Sparse coverage. SPM precursors have weak evidence for renal macrophage modulation. Systemic small molecules reach but at low local concentration.

Synovial macrophages (joint flare site)

Existing biologics work (canakinumab, anakinra). Systemic small molecules. Intra-articular delivery (exosomes, mRNA-IL-1RA) is open and would compete with biologics on cost.

Vessel-wall macrophages (Lp-PLA2)

Brian-specific significance. Persistent Lp-PLA2 elevation across his 2023-2025 panels while hs-CRP normalized. Systemic small-molecule reach is partial; myeloid-tropic LNPs delivering NLRP3-silencing payloads is the genuinely novel exploration vector here. Also: DHA-emphasis omega-3 (RvD1/MaR1) is the closest current OE-aligned tool — see spm-resolution-pathway.md.

Acute flare termination

OE has zero fast-acting tools. Existing options are pharma (colchicine, prednisone, anakinra, canakinumab). mRNA-IL-1RA pulse therapy is the open exploration vector — transient expression matches the short flare window.

Real-time monitoring

No OE coverage. Wearable / microneedle / implantable are open vectors. For self-experiment purposes (self-experiment-protocol.md), continuous UA data would change the kinetics of intervention titration.

Open exploration questions surfaced by the matrix

The cells where 🟡 marks the genuinely novel exploration space, ordered by leverage:

  1. siRNA against URAT1 mRNA via kidney-tropic conjugate. Sequence-specific renal-reabsorption knockdown. Cleaner than benzbromarone-class. Adjacent to inclisiran-style precedent. Zero clinical programs for gout. Mechanism: see androgen-urate-axis.md, gout-pathophysiology.md.

  2. Engineered Faecalibacterium prausnitzii for local butyrate at the gut crypt. Hits both wild-type ABCG2 (PPARγ) and Q141K (HDAC trafficking rescue) per abcg2-modulators.md. Genotype-agnostic; durable colonization avoids the "eat koji daily" adherence problem. Engineering precedent: Sonnenburg lab work on Bacteroides genome editing transfers conceptually.

  3. Myeloid-tropic LNP delivering NLRP3-silencing mRNA / siRNA to vessel-wall macrophages. Brian-pattern Lp-PLA2 persistence is the n=1 case study. Acuitas / Moderna myeloid LNPs exist for oncology; gout repurposing is novel.

  4. Pharmacological chaperone for ABCG2 Q141K folding rescue. CFTR-corrector class precedent (~$10B annual market for ΔF508 correction). Same ATP-binding cassette superfamily. Academic mechanism literature exists; no clinical programs. Could be a small-molecule discovery campaign with AI-era binder design.

4b. Gut-luminal soluble complement regulator (sCR1 / Factor H / DAF/CD55 ectodomain) expressed in GRAS host for CP0 mucosal coverage. Closes the only "honest platform gap" in the OE corpus — complement-c5a-gout.md flags CP0 as having no fermentable coverage; validation-experiments.md §1.21 confirmed zero natural-product C5aR1 antagonists exist. All four candidate proteins are human-endogenous, UniProt-fetchable, AlphaFold-modelled. DAF/CD55 ectodomain (~70 kDa, 4 SCR domains) is the most tractable engineering target (vs. sCR1 at 190 kDa / 30 SCR domains). Zero programs anywhere — all clinical complement regulators target systemic IV delivery. Mucosal-luminal expression is unexplored. comp-006 (2026-05-05): protease-stability analysis of the CD55 soluble ectodomain (aa 35–353) under shio-koji conditions returned HIGH (max risk 0.388, NPr worst protease). The verdict is stalk-contingent — the SCR1–4 domains are well-folded (zero exposed sites); the Ser/Thr-rich stalk (aa 286–353, pLDDT 30–52) drives all exposed-site risk. Next step: comp-007 on the SCR1-4-only truncation (aa 35–285), expected LOW verdict. See wiki/daf-cd55-protease-stability-computational.md.

  1. mRNA-IL-1RA pulse therapy for acute flare termination. Transient expression matches flare window. Zero programs; mechanistically defensible; competes with canakinumab on cost (mRNA manufacturing scales; $300K/yr biologic doesn't).

  2. Engineered Akkermansia muciniphila for mucus-layer barrier repair. Different chassis from yeast/koji. Mucus-resident colonization solves the transit-time problem. Adjacent to commercial Pendulum probiotic.

  3. Bacteriophage-mediated selective suppression of LPS-producing or purine-fermenting gut species. Different from "add-an-organism" thesis. Mechanistically distinct from probiotic addition. No gout programs.

  4. Wearable sweat-based or microneedle continuous UA monitoring. Changes intervention-titration kinetics. UCSD / Stanford research-stage.

  5. Glucoraphanin co-production in engineered koji. Already flagged in abcg2-modulators.md Engineering Implications #1 and the just-added open-questions.md §"Co-engineered substrate-supply mechanisms". Same product, two mechanisms (substrate degradation + substrate supply).

  6. Engineered exosomes carrying NLRP3 inhibitors targeted to CD163+ macrophages. Specifically for vessel-wall and synovial sites. Research-stage chassis; longer horizon than #1-3 above.

Cross-references

Maintenance

  • When a new modality lands in the broader scientific toolset: add it as a row; ask the framing question per cell ("what gout-relevant problem could this open?"); flag the cells where it's genuinely novel.
  • When a new chokepoint, transporter, or biomarker surfaces: add it as a column; re-evaluate which rows light up.
  • When OE makes a new build commitment: mark the cell ✅ and link to the canonical wiki page; the matrix becomes the index.
  • The matrix is a meta-tool for exploration, not a roadmap. Don't pretend a 🟡 cell is committed work; don't pretend a ⚪ cell is forever closed.

Chokepoint candidates surfaced by comp-014 (2026-05-06) — pending formal admit/reject

Two new chokepoint candidates were surfaced by comp-014 Phase 2 (breadth aggregation of 6,798 fungal compounds across ChEMBL + LOTUS + PubMed). Neither has been formally admitted to the matrix as a column; both are pending Phase 3-6 follow-ups.

  • ADA (adenosine deaminase) — purine catabolism enzyme upstream of XO. Fungal-compound coverage via GLPP (G. lucidum) and cordycepin + native pentostatin (C. militaris). ADA modulation changes purine nucleoside flux entering the XO → urate pipeline. (Mechanistic Extrapolation; source: medicinal-mushroom-compound-mapping-computational.md)
  • PINK1/mitophagy — mitochondrial quality-control pathway. PINK1 senses mitochondrial damage and recruits Parkin to initiate mitophagy, clearing damaged mitochondria before they generate the mtROS that triggers NLRP3 (CP2). NLRP3-priming-adjacent — operates upstream of CP2 rather than at NLRP3 assembly directly. (Mechanistic Extrapolation; source: medicinal-mushroom-compound-mapping-computational.md)